AbbVie Rises on Fresh SKYRIZI Data and Supportive Analyst Tone

AbbVie Inc. (ABBV) is up 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be fresh positive Phase 3 data for subcutaneous SKYRIZI in Crohn’s disease, which adds to the company’s case that its next-generation immunology franchise can keep powering growth. The move may also have been helped by a run of supportive analyst price-target updates in recent sessions, reinforcing confidence ahead of AbbVie’s October 30, 2026 earnings report.

Details:

AbbVie announced new Phase 3 AFFIRM results on October 13 showing subcutaneous SKYRIZI produced higher clinical and endoscopic response rates than placebo in adults with moderately to severely active Crohn’s disease.

Additional updates on October 11 highlighted new SKYRIZI and RINVOQ data in inflammatory bowel disease, keeping investor attention on AbbVie’s largest post-Humira growth engines.

Recent analyst actions have stayed constructive, with several firms maintaining positive ratings and some raising price targets during the first half of October.

An October 5 filing updated 2026 earnings guidance to reflect an acquired IPR&D and milestones expense, so today’s gain suggests investors were more focused on pipeline strength and long-term revenue drivers than on that near-term cost item.

Sources:

AbbVie, SEC, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABBV Insider Trading Activity

$ABBV insiders have traded $ABBV stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:

NICHOLAS DONOGHOE (EVP, CHIEF BUS/STRAT OFFICER) sold 32,710 shares for an estimated $8,177,500

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ABBV Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ABBV Hedge Fund Activity

We have seen 2,094 institutional investors add shares of $ABBV stock to their portfolio, and 1,658 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 47,862,796 shares (+inf%) to their portfolio in Q2 2026, for an estimated $12,044,193,985
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 12,914,230 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,249,736,837
FRANKLIN RESOURCES INC added 5,373,163 shares (+36.9%) to their portfolio in Q2 2026, for an estimated $1,352,102,737
DIAMANT ASSET MANAGEMENT, INC. removed 3,654,526 shares (-99.5%) from their portfolio in Q2 2026, for an estimated $919,624,922
CAPITAL WORLD INVESTORS added 3,337,599 shares (+21.1%) to their portfolio in Q2 2026, for an estimated $839,873,412
MARSHALL WACE, LLP added 2,989,451 shares (+281757.9%) to their portfolio in Q2 2026, for an estimated $752,265,449
SG AMERICAS SECURITIES, LLC added 2,849,663 shares (+251.0%) to their portfolio in Q2 2026, for an estimated $717,089,197

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABBV Congressional Stock Trading

Members of Congress have traded $ABBV stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:

REPRESENTATIVE PETE SESSIONS sold up to $50,000 on 09/14.
REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/05.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ABBV Price Targets

Multiple analysts have issued price targets for $ABBV recently. We have seen 7 analysts offer price targets for $ABBV in the last 6 months, with a median target of $273.0.

Here are some recent targets:

Vamil Divan from Guggenheim set a target price of $261.0 on 07/09/2026
Chris Schott from JP Morgan set a target price of $280.0 on 07/09/2026
Carter Gould from Cantor Fitzgerald set a target price of $265.0 on 07/06/2026
Gary Nachman from Canaccord Genuity set a target price of $273.0 on 06/23/2026
David Amsellem from Piper Sandler set a target price of $298.0 on 06/23/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $235.0 on 05/15/2026
Terence Flynn from Morgan Stanley set a target price of $278.0 on 04/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.